Osobliwość wśród cytrusów
Author: admin
<!–
Stock News
–>
September 1, 2017 – By Stephen Andrade
Monarch Capital Management Inc decreased Coca (KO) stake by 12.89% reported in 2016Q4 SEC filing. Monarch Capital Management Inc sold 22,866 shares as Coca (KO)’s stock rose 6.48%. The Monarch Capital Management Inc holds 154,562 shares with $6.41M value, down from 177,428 last quarter. Coca now has $194.97B valuation. The stock increased 0.35% or $0.16 during the last trading session, reaching $45.55. About 6 shares traded. The Coca-Cola Co (NYSE:KO) has declined 0.95% since September 1, 2016 and is downtrending. It has underperformed by 17.65% the SP500.
NUTRAFUELS (OTCMKTS:NTFU) had an increase of 47.89% in short interest. NTFU’s SI was 10,500 shares in September as released by FINRA. Its up 47.89% from 7,100 shares previously. With 36,800 avg volume, 0 days are for NUTRAFUELS (OTCMKTS:NTFU)’s short sellers to cover NTFU’s short positions. The stock increased 0.81% or $0.003 on August 31, reaching $0.341. About shares traded. NutraFuels Inc (OTCMKTS:NTFU) has 0.00% since September 1, 2016 and is . It has underperformed by 16.70% the SP500.
NutraFuels, Inc. manufactures and distributes oral spray nutritional and dietary products. The company has market cap of $25.02 million. The Company’s oral spray products are designed to provide more absorption than capsules or liquid formulas. It currently has negative earnings. The Company’s products include NutraFuels sleep spray; NutraFuels Energy Spray; NutraFuels Garcinia Cambogia Spray; NutraFuels Headache and Pain Spray, and NutraFuels Hair, Skin and Nails Spray.
Investors sentiment increased to 0.94 in 2016 Q4. Its up 0.15, from 0.79 in 2016Q3. It is positive, as 76 investors sold KO shares while 623 reduced holdings. 102 funds opened positions while 503 raised stakes. 2.70 billion shares or 1.56% more from 2.66 billion shares in 2016Q3 were reported. California-based Boltwood Cap Mgmt has invested 1.32% in The Coca-Cola Co (NYSE:KO). Autus Asset Llc holds 16,428 shares or 0.15% of its portfolio. Natixis Asset Mngmt stated it has 0.93% in The Coca-Cola Co (NYSE:KO). Naples Advsr has 20,172 shares for 0.33% of their portfolio. New Mexico Educational Retirement Board has invested 0.8% in The Coca-Cola Co (NYSE:KO). Pettee Inc accumulated 7,750 shares or 0.31% of the stock. Beacon Financial Gru stated it has 1.44% of its portfolio in The Coca-Cola Co (NYSE:KO). Crestpoint Capital Limited Liability Company invested in 29,200 shares. Aviva Public Ltd accumulated 2.79M shares or 0.69% of the stock. Edgar Lomax Com Va invested 0.49% of its portfolio in The Coca-Cola Co (NYSE:KO). Mogy Joel R Invest Counsel Inc owns 0.23% invested in The Coca-Cola Co (NYSE:KO) for 30,234 shares. Bangor Bancshares holds 0.14% or 14,346 shares in its portfolio. Violich Capital Mngmt owns 87,510 shares. Gilman Hill Asset Management Limited Liability Corporation invested in 0.27% or 17,916 shares. Truepoint has 15,726 shares for 0.07% of their portfolio.
Among 18 analysts covering Coca-Cola (NYSE:KO), 7 have Buy rating, 1 Sell and 10 Hold. Therefore 39% are positive. Coca-Cola had 48 analyst reports since July 21, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Thursday, April 21 by Citigroup. As per Wednesday, April 19, the company rating was upgraded by Credit Suisse. Cowen Co maintained the stock with “Hold” rating in Tuesday, August 22 report. The company was maintained on Wednesday, June 29 by Goldman Sachs. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, March 10. The firm has “Buy” rating given on Thursday, October 22 by UBS. The stock of The Coca-Cola Co (NYSE:KO) earned “Buy” rating by RBC Capital Markets on Tuesday, August 1. Barclays Capital reinitiated The Coca-Cola Co (NYSE:KO) on Friday, August 7 with “Equal Weight” rating. The rating was maintained by Goldman Sachs with “Neutral” on Thursday, April 21. BMO Capital Markets maintained The Coca-Cola Co (NYSE:KO) on Wednesday, July 12 with “Hold” rating.
Receive News Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our daily email newsletter.
Caption
Close
Dr. Oz may be America’s most famous doctor, but he doesn’t always give advice that’s FDA-approved. He’s repeatedly come under fire for supporting “miracle cures” that have less-than-scientific backing. When called in front of a Senate hearing on consumer protection in 2014, Dr. Oz was chastised for “melding medical advice, news, and entertainment in a way that harms consumers.”
Dr. Oz may be America’s most famous doctor, but he doesn’t always give advice that’s FDA-approved. He’s repeatedly come under fire for supporting “miracle cures” that have less-than-scientific backing. When
… more
Photo: Lionel Cironneau/Associated Press
The Food and Drug Administration on Wednesday approved a groundbreaking cancer treatment for childhood leukemia that uses patients’ own genetically altered immune cells to fight the disease. It is the first gene therapy to be allowed in the United States – a “historic” approval, the agency said.
The decision clears the Novartis drug, called Kymriah, for treatment with children and young adults whose illness doesn’t respond to traditional approaches. That group numbers only 600 or so patients a year in this country. But the customized treatment is also being tested for a range of diseases from non-Hodgkin lymphoma and multiple myeloma to solid tumors, and its approval signals a new chapter in treating cancer by mobilizing the body’s own immune system.
“We’re entering a new frontier in medical innovation with the ability to reprogram a patient’s own cells to attack a deadly cancer,” FDA Commissioner Scott Gottlieb said in a statement. “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.”
Unlike traditional gene therapy, the new treatment doesn’t replace disease-causing genes with healthy ones. Instead, in a complicated process developed at the University of Pennsylvania, white blood cells called T cells are extracted from the patient and sent to a manufacturing center to be modified to include a new gene that directs the T cells to target and kill leukemia cells. Those T cells then are infused back into the patient.
The treatment is approved for patients up to 25 years of age with B-cell acute lymphoblastic leukemia that doesn’t respond to treatment or that returns after initial treatment – as happens in up to 20 percent of patients, according to the FDA.
Taylor Hammond, a 10-year-old battling leukemia, caught a pass from Sam Darnold and scored a touchdown during a special practice with the USC Trojans football team.
Media: Sports Illustrated
In a pivotal study of five dozen patients, the drug induced remission in more than 80 percent. But some patients relapsed, and doctors are still monitoring the rest to see how long the drug’s effect will last.
The treatment, which is expected to be costly, can cause serious side effects including high fevers and neurological problems. A drug called tocilizumab can often successfully treat those complications.
Because of the risks involved, the FDA is requiring that hospitals and medical staff using Kymriah be specially trained.
Novartis executives said in a call with reporters that the therapy would cost $475,000 per treatment and that the company expects to have 20 certified medical centers ready within a month for patients to begin undergoing treatment. The company will introduce a pricing model based on how well the drug works; a patient will not be charged for the therapy if it doesn’t show signs of working within a month.
Of the 600 patients in the United States who are eligible for Kymriah, most are children who have insurance coverage through their parents’ insurance, Medicaid or the federal Children’s Health Insurance Program. Novartis has set up a patient-assistance program that can be used to help families who lack insurance or have coverage that falls short for this treatment. It also has a program to assist with travel expenses.
Moving forward, Chief Executive Joe Jimenez said, the company plans to price the drug differently depending on which specific disease it is treating. If Kymriah is later approved for another type of cancer in which it is less effective, the price could theoretically be lower.
Novartis plans to file for FDA approval of Kymriah for a type of non-Hodgkin lymphoma that affects adults later this year.
California-based Kite Pharma, which is being acquired by Gilead Sciences, also has applied for FDA approval for use of its own CAR T-cell therapy in lymphoma patients.